XML 67 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1

Collaboration and Licensing Agreements (Details)					1 Months Ended																3 Months Ended				12 Months Ended
	Nov. 12, 2021 USD ($) shares	Oct. 01, 2021 USD ($) item D $ / shares	Feb. 04, 2020 USD ($) shares	Mar. 29, 2019 USD ($)	Dec. 31, 2021 USD ($) item shares	Nov. 30, 2021 USD ($)	Sep. 30, 2021 USD ($) shares	Aug. 31, 2021	Jun. 30, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares	Nov. 30, 2020 USD ($) item	Aug. 31, 2020 USD ($) item	Apr. 30, 2020 USD ($)	Jan. 31, 2020 USD ($) item Option	Dec. 31, 2019 USD ($)	Nov. 30, 2019 USD ($)	Mar. 31, 2019 USD ($) company	Feb. 28, 2019	Oct. 31, 2017 USD ($) shares	Jun. 30, 2016 item	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2020 item	Sep. 30, 2019 USD ($)	Dec. 31, 2021 USD ($) item Program shares	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($) item	Dec. 31, 2017 USD ($) shares	May 31, 2018 USD ($)	Sep. 30, 2015 USD ($) item
Collaboration research and licensing agreements
Receivable					$ 66,384,000					$ 11,443,000															$ 66,384,000	$ 11,443,000
Proceeds from sale of common stock																									28,920,000
Revenue recorded																									275,111,000	122,694,000	$ 156,700,000
Other income																									(1,274,000)	95,000	(256,000)
Impairment																									762,000
Net gains recognized on sale of equity securities																									18,301,000	801,000
Unrealized gains (losses) recognized on equity securities																									20,988,000	(696,000)
Net gains recognized on equity securities																									39,289,000	105,000
Deferred revenue					37,300,000					92,600,000															37,300,000	92,600,000
Licensing
Collaboration research and licensing agreements
Revenue recorded																									80,800,000	50,200,000	112,200,000
Royalties
Collaboration research and licensing agreements
Revenue recorded																									80,300,000	17,800,000	5,000,000.0
Milestone
Collaboration research and licensing agreements
Revenue recorded																									21,000,000.0	50,200,000	23,200,000
Research collaboration
Collaboration research and licensing agreements
Revenue recorded																									93,000,000.0	4,500,000	16,300,000
Aimmune
Collaboration research and licensing agreements
Revenue recorded																										9,600,000
Alexion Pharmaceuticals, Inc.
Collaboration research and licensing agreements
Revenue recorded																									$ 22,200,000	26,200,000	13,000,000.0
Amgen, Inc.
Collaboration research and licensing agreements
Revenue recorded																											5,000,000.0
Astellas
Collaboration research and licensing agreements
Revenue recorded																										3,500,000	14,000,000.0
Astria/Catabasis | Common Stock
Collaboration research and licensing agreements
Shares received in noncash transaction | shares									259,206
Shares issued upon conversion | shares									3,580,539
Reverse stock split ratio								0.166
Number of shares | shares																									3,839,745
Genentech
Collaboration research and licensing agreements
Revenue recorded																									$ 2,500,000	3,500,000	113,900,000
Gilead
Collaboration research and licensing agreements
Revenue recorded																										13,500,000
MiRagen/Viridian
Collaboration research and licensing agreements
Revenue recorded																									7,500,000	6,000,000.0
MorphoSys
Collaboration research and licensing agreements
Revenue recorded																									18,400,000	39,000,000.0
Novartis
Collaboration research and licensing agreements
Revenue recorded																									43,100,000		10,000,000.0
Omeros
Collaboration research and licensing agreements
Revenue recorded																										5,000,000.0
Zenas Bio Pharma Limited
Collaboration research and licensing agreements
Revenue recorded																									14,900,000	16,100,000
Vir
Collaboration research and licensing agreements
Revenue recorded																									52,700,000	300,000	800,000
License, Development, and Commercialization Agreement | Aimmune
Collaboration research and licensing agreements
Transaction price			$ 9,600,000
Nonrefundable upfront payment			5,000,000.0
Potential milestone payment			$ 385,000,000.0
Revenue recognized																									0	9,600,000
Shares received in noncash transaction | shares			156,238
Purchase amount of share options or equity in noncash transaction			$ 4,600,000
Deferred revenue					0					$ 0															0	0
Option and license agreement | Alexion Pharmaceuticals, Inc.
Collaboration research and licensing agreements
Receivable					10,800,000																				10,800,000
Revenue recognized																									22,200,000	26,200,000	13,000,000.0
Deferred revenue					0																				0
Option and license agreement | Alexion Pharmaceuticals, Inc. | Royalties
Collaboration research and licensing agreements
Revenue recognized																									22,200,000	16,200,000	5,000,000.0
Option and license agreement | Alexion Pharmaceuticals, Inc. | Milestone
Collaboration research and licensing agreements
Revenue recognized																										10,000,000.0	8,000,000.0
Research and License Agreement | Amgen, Inc.
Collaboration research and licensing agreements
Potential milestone payment																														$ 255,000,000.0
Revenue recognized																									0	0	5,000,000.0
Deferred revenue					0																				0
Research and License Agreement | Amgen, Inc. | Discovery Program
Collaboration research and licensing agreements
Revenue recognized																								$ 5,000,000.0
Previous targets which bispecific technology will be applied | item																														5
Research and License Agreement | Astellas
Collaboration research and licensing agreements
Nonrefundable upfront payment				$ 15,000,000.0
Potential milestone payment				240,000,000.0
Revenue recognized																									0	3,500,000	14,000,000.0
Deferred revenue					0																				0
Research and License Agreement | Astellas | Bispecific
Collaboration research and licensing agreements
Revenue recognized																											13,600,000
Research and License Agreement | Astellas | Research service
Collaboration research and licensing agreements
Revenue recognized				1,400,000
Research and License Agreement | Astellas | Milestone
Collaboration research and licensing agreements
Revenue recognized																										2,500,000
Research and License Agreement | Novartis | Milestone
Collaboration research and licensing agreements
Revenue recognized																									3,000,000.0
Collaboration and License Agreement | Genentech
Collaboration research and licensing agreements
Transaction price																	$ 120,000,000.0
Nonrefundable upfront payment																	$ 120,000,000.0
Percentage of profits on net sales of the product																	45.00%
Research license term																	2 years	2 years
Revenue recognized																									2,500,000	3,500,000	113,900,000
Number of companies that conduct integrated research plan | company																	2
Cost sharing receivable (payable)					(2,200,000)																				(2,200,000)
Collaboration and License Agreement | Genentech | XmAb306
Collaboration research and licensing agreements
Standalone selling price																	$ 111,700,000
Collaboration and License Agreement | Genentech | XmAb435
Collaboration research and licensing agreements
Standalone selling price																	4,100,000
Collaboration and License Agreement | Genentech | Research service
Collaboration research and licensing agreements
Transaction price					8,300,000																				8,300,000
Revenue recognized																									2,500,000	3,500,000	2,200,000
Deferred revenue					0																				0
Standalone selling price																	4,200,000
Collaboration and License Agreement | Genentech | Licensing
Collaboration research and licensing agreements
Transaction price																	111,700,000
Collaboration and License Agreement | Genentech | Maximum | XmAb306
Collaboration research and licensing agreements
Potential milestone payment																	160,000,000.0
Collaboration and License Agreement | Genentech | Maximum | XmAb435
Collaboration research and licensing agreements
Potential milestone payment																	180,000,000.0
Collaboration and License Agreement | Genentech | Cost approach | Research service
Collaboration research and licensing agreements
Standalone selling price																	8,500,000
Collaboration and License Agreement | Genentech | Cost approach | Licensing
Collaboration research and licensing agreements
Standalone selling price																	$ 114,400,000
Collaboration and License Agreement | Janssen Biotech, Inc
Collaboration research and licensing agreements
Transaction price											$ 50,000,000.0
Nonrefundable upfront payment											50,000,000.0
Potential milestone payment											$ 662,500,000
Research license term		2 years
Revenue recognized					5,000,000.0																				113,800,000	0
Deferred revenue					$ 37,300,000																				$ 37,300,000
Percentage of funding for development costs											20.00%
Percentage of co-detailing activities											30.00%
Number of collaboration and license agreements | item					2																				2
Collaboration and License Agreement | Janssen Biotech, Inc | Milestone
Collaboration research and licensing agreements
Revenue recognized																									$ 5,000,000.0
Collaboration and License Agreement | Janssen Biotech, Inc | Research collaboration
Collaboration research and licensing agreements
Revenue recognized																									50,000,000.0
Collaboration and License Agreement | MorphoSys
Collaboration research and licensing agreements
Revenue recognized																											0
Deferred revenue					$ 0																				0
Collaboration and License Agreement | MorphoSys | Royalties
Collaboration research and licensing agreements
Revenue recognized																									5,900,000	1,500,000
Contract asset					1,900,000																				1,900,000
Collaboration and License Agreement | MorphoSys | Milestone
Collaboration research and licensing agreements
Revenue recognized																									12,500,000	37,500,000
Collaboration and License Agreement | Novartis
Collaboration research and licensing agreements
Receivable					600,000																				600,000
Revenue recognized																									43,100,000	0	10,000,000.0
Deferred revenue					0																				$ 0
Remaining cost sharing settlement amount																$ 1,400,000
Collaboration and License Agreement | Novartis | Bispecific FC Technologies
Collaboration research and licensing agreements
Number of development stage products | item																				2
Collaboration and License Agreement | Novartis | Global Discovery Program
Collaboration research and licensing agreements
Number of programs delivered | Program																									2
Proceeds from milestone payments															$ 10,000,000.0									10,000,000.0
Revenue recognized																								$ 10,000,000.0	$ 40,100,000			$ 40,100,000
Collaboration and License Agreement | Novartis | Global Discovery Program | Maximum
Collaboration research and licensing agreements
Number of antibody targets for which bispecific technology applied | item																				4
Collaboration and License Agreement | Novartis | FC Licenses | Maximum
Collaboration research and licensing agreements
Number of targets against which non-exclusive license is provided | item																				10
Technology License Agreement | Quellis | Maximum
Collaboration research and licensing agreements
Potential milestone payment																													$ 66,000,000.0
Technology License Agreement | Astria/Catabasis
Collaboration research and licensing agreements
Impairment					800,000																				800,000
Unrealized gains (losses) recognized on equity securities																									4,500,000
Deferred revenue					0																				0
Technology License Agreement | Astria/Catabasis | Common Stock
Collaboration research and licensing agreements
Reverse stock split ratio								0.166
Technology License Agreement | Gilead
Collaboration research and licensing agreements
Transaction price														$ 13,500,000
Nonrefundable upfront payment														6,000,000.0
Potential milestone payment														$ 67,000,000.0
Revenue recognized													$ 7,500,000												0	13,500,000
Deferred revenue					$ 0																				0
Options exercised														3									3
Number of compounds | item														3
Option fee														$ 7,500,000
Technology License Agreement | MiRagen/Viridian
Collaboration research and licensing agreements
Number of antibodies | item					3
Transaction price					$ 6,000,000.0																				6,000,000.0
Research license term					1 year
Revenue recognized																									7,500,000	6,000,000.0
Shares received in noncash transaction | shares					394,737					322,407
Purchase amount of share options or equity in noncash transaction					$ 7,500,000					$ 6,000,000.0
Deferred revenue					$ 0																				0
Technology License Agreement | MiRagen/Viridian | Common Stock
Collaboration research and licensing agreements
Shares received in noncash transaction | shares					394,737					322,407
Technology License Agreement | MiRagen/Viridian | Maximum
Collaboration research and licensing agreements
Potential milestone payment					$ 24,750,000					$ 55,000,000.0															24,750,000	55,000,000.0
Technology License Agreement | MiRagen/Viridian | Xtend Fc Technology
Collaboration research and licensing agreements
Transaction price					6,000,000.0																				6,000,000.0
Technology License Agreement | MiRagen/Viridian | Antibody Libraries
Collaboration research and licensing agreements
Transaction price					7,500,000																				7,500,000
Technology License Agreement | Omeros
Collaboration research and licensing agreements
Nonrefundable upfront payment												$ 5,000,000.0
Revenue recognized																									0	5,000,000.0
Deferred revenue					0																				0
Number of additional antibodies | item												3
Technology License Agreement | Omeros | Maximum
Collaboration research and licensing agreements
Potential milestone payment												$ 65,000,000.0
Technology License Agreement | Bristol Myers Squibb
Collaboration research and licensing agreements
Revenue recognized																									0
Deferred revenue					0																				0
License Agreement | INmune
Collaboration research and licensing agreements
Revenue recognized																									0	0	0
Shares received in noncash transaction | shares																			1,585,000
Purchase amount of share options or equity in noncash transaction																			$ 10,000,000.0
Consideration on sale of option									$ 18,300,000
Cash consideration on sale of option									15,000,000.0
Shares issues on sale of option value									3,300,000
Net gains recognized on sale of equity securities									$ 18,300,000																18,300,000
Unrealized gains (losses) recognized on equity securities																									$ 15,100,000
Option term																			6 years
Number of shares | shares									192,533
License Agreement | INmune | Common Stock
Collaboration research and licensing agreements
Shares received in noncash transaction | shares																												1,585,000
Purchase amount of share options or equity in noncash transaction							$ 800,000
Cash consideration on sale of option									$ 15,000,000.0
Shares issued upon conversion | shares									192,533
Unrealized gains (losses) recognized on equity securities																					$ 2,000,000.0
Gain on fair value of option																					1,100,000
Net gains recognized on equity securities							$ 900,000
Additional equity interests (as a percentage)									10.00%																			10.00%
Option to acquire shares | shares																			108,000									108,000
Number of shares | shares							108,000																		1,885,533
License Agreement | INmune | Maximum
Collaboration research and licensing agreements
Additional equity interests (as a percentage)																			10.00%
License Agreement | INmune | Other Income
Collaboration research and licensing agreements
Unrealized gains (losses) recognized on equity securities																						$ 27,800,000
License Agreement | INmune | Other Income | Common Stock
Collaboration research and licensing agreements
Net gains recognized on equity securities																					$ 900,000
License Agreement | Zenas Bio Pharma Limited
Collaboration research and licensing agreements
Transaction price						$ 14,900,000					$ 16,100,000
Revenue recognized																									$ 14,900,000	16,100,000
Purchase amount of share options or equity in noncash transaction											$ 16,100,000
Deferred revenue					$ 0																				$ 0
Percentage of equity of private company						15.00%					15.00%
Number of drug candidates | item											3
Milestones or royalties in transaction price						$ 0					$ 0
Number of collaboration and license agreements | item					2																				2
Patent License Agreement | Vir
Collaboration research and licensing agreements
Receivable					$ 45,000,000.0																				$ 45,000,000.0
Potential milestone payment															154,500,000												154,500,000
Revenue recognized																									52,700,000	300,000	800,000
Contract asset									$ 500,000													$ 500,000
Deferred revenue					0																				0
Upfront and milestone payment received																											$ 1,500,000
Number of different target programs | item																											2
Patent License Agreement | Vir | Royalties
Collaboration research and licensing agreements
Revenue recognized																									52,200,000
Second Collaboration And License Agreement [Member] | Janssen Biotech, Inc
Collaboration research and licensing agreements
Discount on proceeds from sale																									3,900,000
Transaction price					96,100,000																				96,100,000
Share development percentage						80.00%
Number of candidates for which option to advance for development and commercialization | item		4
Proceeds from sale of common stock	$ 28,900,000
Nonrefundable upfront payment		$ 100,000,000.0																							100,000,000.0
Potential milestone payment		$ 1,187,500,000
Research license term		2 years
Number of drug candidates | item		4
Percentage of responsibility for development costs						20.00%
Second Collaboration And License Agreement [Member] | Janssen Biotech, Inc | Research service
Collaboration research and licensing agreements
Performance obligation					37,600,000	$ 37,600,000																			37,600,000
Revenue recognized																									300,000
Standalone selling price					37,600,000																				37,600,000
Second Collaboration And License Agreement [Member] | Janssen Biotech, Inc | Licensing
Collaboration research and licensing agreements
Transaction price					58,500,000																				58,500,000
Revenue recognized						58,500,000
Standalone selling price					58,500,000																				58,500,000
Second Collaboration And License Agreement [Member] | Johnson & Johnson Innovation, JJDC, Inc. | Common Stock
Collaboration research and licensing agreements
Total equity shares | shares	748,062
Number of trading days | D		30
Weighted average price | $ / shares		$ 33.4197
Proceeds from sale of common stock		$ 25,000,000.0
Second Collaboration And License Agreement [Member] | Zenas Bio Pharma Limited
Collaboration research and licensing agreements
Warrants						14,900,000
Potential milestone payment						$ 470,000,000.0
Development-based | License, Development, and Commercialization Agreement | Aimmune
Collaboration research and licensing agreements
Potential milestone payment			22,000,000.0
Development-based | Research and License Agreement | Astellas
Collaboration research and licensing agreements
Potential milestone payment				32,500,000
Development-based | Collaboration and License Agreement | Janssen Biotech, Inc
Collaboration research and licensing agreements
Potential milestone payment											161,900,000
Development-based | Technology License Agreement | Quellis
Collaboration research and licensing agreements
Potential milestone payment																													6,000,000.0
Development-based | Technology License Agreement | Gilead
Collaboration research and licensing agreements
Potential milestone payment														10,000,000.0
Development-based | Technology License Agreement | MiRagen/Viridian
Collaboration research and licensing agreements
Potential milestone payment					1,750,000					10,000,000.0															1,750,000	10,000,000.0
Development-based | Technology License Agreement | Omeros
Collaboration research and licensing agreements
Potential milestone payment												15,000,000.0
Development-based | Patent License Agreement | Vir
Collaboration research and licensing agreements
Potential milestone payment															4,500,000												$ 4,500,000
Development-based | Second Collaboration And License Agreement [Member] | Janssen Biotech, Inc
Collaboration research and licensing agreements
Potential milestone payment		289,400,000
Regulatory-based | License, Development, and Commercialization Agreement | Aimmune
Collaboration research and licensing agreements
Potential milestone payment			53,000,000.0
Regulatory-based | Research and License Agreement | Astellas
Collaboration research and licensing agreements
Potential milestone payment				57,500,000
Regulatory-based | Collaboration and License Agreement | Janssen Biotech, Inc
Collaboration research and licensing agreements
Potential milestone payment											240,600,000
Regulatory-based | Technology License Agreement | Quellis
Collaboration research and licensing agreements
Potential milestone payment																													30,000,000.0
Regulatory-based | Technology License Agreement | Gilead
Collaboration research and licensing agreements
Potential milestone payment														27,000,000.0
Regulatory-based | Technology License Agreement | MiRagen/Viridian
Collaboration research and licensing agreements
Potential milestone payment					3,000,000.0					20,000,000.0															3,000,000.0	20,000,000.0
Regulatory-based | Technology License Agreement | Omeros
Collaboration research and licensing agreements
Potential milestone payment												25,000,000.0
Regulatory-based | Patent License Agreement | Vir
Collaboration research and licensing agreements
Potential milestone payment															30,000,000.0												30,000,000.0
Regulatory-based | Second Collaboration And License Agreement [Member] | Janssen Biotech, Inc
Collaboration research and licensing agreements
Potential milestone payment		378,100,000
Sales-based | License, Development, and Commercialization Agreement | Aimmune
Collaboration research and licensing agreements
Potential milestone payment			$ 310,000,000.0
Sales-based | Research and License Agreement | Astellas
Collaboration research and licensing agreements
Potential milestone payment				$ 150,000,000.0
Sales-based | Collaboration and License Agreement | Janssen Biotech, Inc
Collaboration research and licensing agreements
Potential milestone payment											$ 260,000,000.0
Sales-based | Technology License Agreement | Quellis
Collaboration research and licensing agreements
Potential milestone payment																													$ 30,000,000.0
Sales-based | Technology License Agreement | Gilead
Collaboration research and licensing agreements
Potential milestone payment														$ 30,000,000.0
Sales-based | Technology License Agreement | MiRagen/Viridian
Collaboration research and licensing agreements
Potential milestone payment					$ 20,000,000.0					$ 25,000,000.0															$ 20,000,000.0	$ 25,000,000.0
Sales-based | Technology License Agreement | Omeros
Collaboration research and licensing agreements
Potential milestone payment												$ 25,000,000.0
Sales-based | Patent License Agreement | Vir
Collaboration research and licensing agreements
Potential milestone payment															$ 120,000,000.0												$ 120,000,000.0
Sales-based | Second Collaboration And License Agreement [Member] | Janssen Biotech, Inc
Collaboration research and licensing agreements
Potential milestone payment		$ 520,000,000.0

X

- Definition

Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522

+ Details

Name:	us-gaap_AccountsReceivableNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044

+ Details

Name:	us-gaap_ContractWithCustomerAssetNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586

+ Details

Name:	us-gaap_ConversionOfStockSharesIssued1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714

+ Details

Name:	us-gaap_EquitySecuritiesFvNiGainLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(3)(d))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

Name:	us-gaap_EquitySecuritiesFvNiRealizedGainLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(3)(d))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714

+ Details

Name:	us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of cumulative impairment loss on investment in equity security without readily determinable fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714

+ Details

Name:	us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 8A
-URI http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562

+ Details

Name:	us-gaap_ImpairmentOfInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of income (expense) related to nonoperating activities, classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

Name:	us-gaap_OtherNonoperatingIncomeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:	us-gaap_SharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770

+ Details

Name:	us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.

+ References

No definition available.

+ Details

Name:	us-gaap_WarrantsAndRightsOutstanding
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The amount of cash consideration received from sale of option.

+ References

No definition available.

+ Details

Name:	xncr_CashConsiderationOnSaleOfOption
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount received as settlement of projected remaining cost sharing due.

+ References

No definition available.

+ Details

Name:	xncr_CollaborationArrangementRemainingCostSharingSettlementAmount
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the number of candidates for which bispecific drug developed.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeAgreementBispecificDrugDevelopmentNumberOfCandidates
Namespace Prefix:	xncr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the number of antibody targets for which bispecific technology applied.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeAgreementBispecificTechnologyAppliedNumberOfAntibodyTargets
Namespace Prefix:	xncr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the number of FC technology targets for which non-exclusive license is provided.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeAgreementNonExclusiveLicenseProvidedNumberOfFcTechnologiesTargets
Namespace Prefix:	xncr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the number of options exercised under a collaborative agreement.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeAgreementNumberOfOptionsExercised
Namespace Prefix:	xncr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the number of candidates for which option to advance for development and commercialization.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeAgreementOptionToAdvanceNumberOfCandidatesForDevelopmentAndCommercialization
Namespace Prefix:	xncr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the percentage of profit on net sales of the product, if the company elects to participate in development.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeAgreementPercentageOfProfitOnNetSales
Namespace Prefix:	xncr_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the percentage of responsibility assumed for development costs, if the company elects to participate in development.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeAgreementPercentageOfResponsibilityAssumedForDevelopmentCosts
Namespace Prefix:	xncr_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the percentage of share assumed by the counter-party for development costs.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeAgreementSharePercentageOfDevelopmentCostByCounterparty
Namespace Prefix:	xncr_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of companies that conduct integrated research plan for programs to be conducted.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeAndLicensingAgreementsNumberOfCompaniesThatConductIntegratedResearchPlan
Namespace Prefix:	xncr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the amount of discount on the proceeds from a sale associated with a collaboration agreement.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeArrangementDiscountOnProceedsReceivedFromSale
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the amount of nonrefundable upfront fees as provided under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeArrangementNonrefundableUpfrontFees
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The number of additional antibodies in a collaboration agreement.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeArrangementNumberOfAdditionalAntibodies
Namespace Prefix:	xncr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of antibodies selected for further development as per the agreement.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeArrangementNumberOfAntibodiesForFurtherDevelopment
Namespace Prefix:	xncr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the number of compounds.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeArrangementNumberOfCompounds
Namespace Prefix:	xncr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the number of different target programs under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeArrangementNumberOfTargetPrograms
Namespace Prefix:	xncr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the amount of option fee that must be paid by counterparty with respect to each target for which the option is exercised as per the terms of the collaboration agreement.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeArrangementOptionFee
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the option term expiring after delivery of the data from a Phase 2 proof-of-concept clinical trial under a collaboration agreement.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeArrangementOptionTermAfterDeliveryOfDataFromPhase2ProofOfConceptClinicalTrial
Namespace Prefix:	xncr_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the amount of interest held in a private company.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeArrangementPercentageEquityPrivateCompany
Namespace Prefix:	xncr_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of receivable (payable) within a collaborative agreement that is associated with cost-sharing development activities.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeArrangementReceivablePayableRelatedToCostSharingDevelopmentActivities
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Represents the research license term under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeArrangementResearchLicenseTerm
Namespace Prefix:	xncr_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The selling price at which the entity would sell a good or service separately to a customer.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeArrangementStandaloneSellingPrice
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of transaction price under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeArrangementTransactionPrice
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Represents the amount of the upfront and milestone payment received under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	xncr_CollaborativeArrangementUpfrontAndMilestonePayment
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of consideration on sale of option.

+ References

No definition available.

+ Details

Name:	xncr_ConsiderationOnSaleOfOption
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of consideration in equity on sale of option.

+ References

No definition available.

+ Details

Name:	xncr_ConsiderationOnSaleOfOptionEquityIssuedValue
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of fair value option gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

+ References

No definition available.

+ Details

Name:	xncr_EquitySecuritiesFvNiFairValueOptionGainLoss
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of milestones or royalties in the transaction price.

+ References

No definition available.

+ Details

Name:	xncr_MilestonesOrRoyaltiesInTransactionPrice
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The number of shares that can be received [noncash or part noncash] on exercise of option. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

No definition available.

+ Details

Name:	xncr_NonCashOrPartNonCashAcquisitionNonCashFinancialOrEquityInstrument
Namespace Prefix:	xncr_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount shares or share options could be purchased for in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

No definition available.

+ Details

Name:	xncr_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationShareValue
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The number of shares received [noncash or part noncash] for consideration of a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

No definition available.

+ Details

Name:	xncr_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesReceived
Namespace Prefix:	xncr_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of collaboration and license agreement.

+ References

No definition available.

+ Details

Name:	xncr_NumberOfCollaborationAndLicenseAgreement
Namespace Prefix:	xncr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Represents the number of development stage products that incorporate the company's bispecific Fc technology.

+ References

No definition available.

+ Details

Name:	xncr_NumberOfDevelopmentStageProducts
Namespace Prefix:	xncr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents number of programs delivered.

+ References

No definition available.

+ Details

Name:	xncr_NumberOfProgramsDelivered
Namespace Prefix:	xncr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the number of common equity shares acquired or held in association with a collaboration agreement.

+ References

No definition available.

+ Details

Name:	xncr_NumberOfSharesAcquired
Namespace Prefix:	xncr_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The percentage of additional equity interests available to be obtained in a license agreement.

+ References

No definition available.

+ Details

Name:	xncr_PercentageOfAdditionalEquityInterests
Namespace Prefix:	xncr_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of co-detailing activities.

+ References

No definition available.

+ Details

Name:	xncr_PercentageOfCoDetailingActivities
Namespace Prefix:	xncr_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Percentage of funding for development costs.

+ References

No definition available.

+ Details

Name:	xncr_PercentageOfFundingForDevelopmentCosts
Namespace Prefix:	xncr_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Represents information in which bispecific technology will be applied to previous targets

+ References

No definition available.

+ Details

Name:	xncr_PreviousTargetsWhichBispecificTechnologyWillBeApplied
Namespace Prefix:	xncr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

The amount of cash inflow from milestone payments received.

+ References

No definition available.

+ Details

Name:	xncr_ProceedsFromMilestonePaymentReceived
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the amount of consideration that will be recognized upon full completion of milestones set forth in a collaborative agreement between two parties.

+ References

No definition available.

+ Details

Name:	xncr_RevenueRecognitionMilestoneMethodPending
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Number of trading days for volume weighted average trading days.

+ References

No definition available.

+ Details

Name:	xncr_VolumeWeightedAverageSharePriceNumberOfTradingDays
Namespace Prefix:	xncr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=xncr_MilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=xncr_CollaborationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xncr_AimmuneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xncr_AlexionPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xncr_AmgenIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xncr_AstellasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xncr_CatabasisPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xncr_GenentechMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xncr_GileadMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xncr_MiragenViridianMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xncr_MorphoSysMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xncr_NovartisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xncr_OmerosCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xncr_ZenasBioPharmaLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xncr_VirBiotechnologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xncr_LicenseDevelopmentAndCommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xncr_OptionAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xncr_ResearchAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	xncr_CollaborationAndLicensingProgramsAxis=xncr_DiscoveryProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=xncr_BispecificProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=xncr_ResearchActivityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xncr_CollaborationAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=xncr_Xmab306ProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=xncr_Xmab435ProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ValuationTechniqueAxis=us-gaap_CostApproachValuationTechniqueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xncr_JanssenBiotechIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	xncr_CollaborationAndLicensingProgramsAxis=xncr_BispecificFcTechnologiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	xncr_CollaborationAndLicensingProgramsAxis=xncr_GlobalDiscoveryProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	xncr_CollaborationAndLicensingProgramsAxis=xncr_FcLicensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xncr_TechnologyLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xncr_QuellisBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	xncr_CollaborationAndLicensingProgramsAxis=xncr_XtendFcTechnologyLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	xncr_CollaborationAndLicensingProgramsAxis=xncr_AntibodyLibrariesLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xncr_BristolMyersSquibbMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xncr_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xncr_InmuneBioIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xncr_PatentLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xncr_SecondCollaborationAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=xncr_JohnsonJohnsonInnovationJjdcInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	xncr_PotentialMilestonesTypeAxis=xncr_DevelopmentBasedMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	xncr_PotentialMilestonesTypeAxis=xncr_RegulatoryBasedMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	xncr_PotentialMilestonesTypeAxis=xncr_SalesBasedMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: